Long-Term Benefits of BRIUMVI® in Treating Relapsing Multiple Sclerosis
Recently, TG Therapeutics, Inc. (NASDAQ: TGTX) presented exciting five-year findings from the ULTIMATE I & II Phase 3 trials for BRIUMVI® (ublituximab-xiiy) at a significant conference. This data highlights BRIUMVI’s effectiveness and safety in managing relapsing forms of multiple sclerosis (RMS).
Clinical Progress and Effectiveness
After five years, an impressive 92% of patients reported no progression of disability following the start of BRIUMVI treatment. Throughout this period, the annualized relapse rates were remarkably low, dropping to just 0.020, which translates to about one relapse occurring every fifty years of treatment.
Insights from Experts
Dr. Bruce Cree from UCSF Weill Institute emphasized how significant these findings are. He pointed out that sustained clinical effectiveness is crucial for both patients and healthcare providers when considering strong treatment options. This reinforces BRIUMVI’s potential to positively impact individuals living with RMS.
Company's Outlook
Michael S. Weiss, the Chairman and CEO of TG Therapeutics, expressed optimism about the encouraging results. He noted that the long-term benefits of initiating treatment early were substantially better for patients compared to those who switched from teriflunomide. These outcomes reinforce BRIUMVI's position as a dependable treatment for RMS.
Consistent Safety Profile
Over the five-year treatment period, BRIUMVI demonstrated a stable safety profile. Importantly, no new safety signals have emerged, which boosts confidence in its long-term use. Moreover, patients maintained stable immunoglobulin levels, showing no heightened risk of serious infections with extended treatment.
Key Data from Clinical Insights
- Annualized relapse rates significantly decreased over the five-year period, indicating a lasting positive treatment effect.
- Patients transitioning from teriflunomide to BRIUMVI experienced a dramatic 58.4% reduction in relapse rates in the first year of the extension trial.
- Only 8% of patients had confirmed disability progression after five years, compared to 14.3% among those who switched from teriflunomide.
- 17% of patients receiving continuous BRIUMVI treatment showed meaningful improvements in disability at the five-year checkpoint.
- No new safety concerns have surfaced, affirming the drug's stability and safety throughout long-term use.
What is BRIUMVI®?
BRIUMVI is a specialized monoclonal antibody that specifically targets CD20-expressing B-cells, which play a significant role in the pathology of RMS. By employing advanced glycoengineering methods, it optimizes efficacy while keeping the dosage minimal, making it a promising treatment option for adults dealing with RMS.
Ongoing Research Initiatives
TG Therapeutics is actively growing its research on BRIUMVI and its potential applications across various B-cell disorders. Their commitment to creating effective therapies for RMS and related conditions shows their dedication to improving patient outcomes and enhancing quality of life.
Frequently Asked Questions
What is BRIUMVI® used for?
BRIUMVI is prescribed for the treatment of adults with relapsing forms of multiple sclerosis, which includes relapsing-remitting and active secondary progressive MS.
How effective is BRIUMVI® according to recent studies?
Recent studies show that 92% of patients remained free from disability progression and experienced low annual relapse rates after five years of treatment.
What does the long-term safety profile of BRIUMVI® look like?
BRIUMVI has maintained a consistent safety profile over the five-year period, with no new safety issues reported during treatment.
What are the main benefits of switching to BRIUMVI® from teriflunomide?
Patients who switch to BRIUMVI saw a significant reduction in relapse rates, indicating improved management of their condition.
How does BRIUMVI® work in the body?
BRIUMVI targets CD20-expressing B-cells to effectively deplete them, which is essential for managing the autoimmune activities associated with MS.
